Login to Your Account



Genentech, OSI Wait On Tarceva Verdict, Start Phase IIIb Program

By Karen Pihl-Carey


Monday, September 13, 2004
Less than two months after filing a new drug application for Tarceva to treat non-small-cell lung cancer, Genentech Inc. and OSI Pharmaceuticals Inc. started a Phase IIIb study of the drug. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription